Create Medic Co Ltd

Create Medic Co Ltd maintains a strong liquidity position, with a current ratio of 7.03 and cash and equivalents of ¥5.83 billion, representing 29% of total assets. The company’s price-to-book ratio of 0.58 and price-to-tangible-book ratio of 0.58 suggest a discount to net asset value, while the price-to-earnings ratio of 13.17 and EV/EBITDA of 3.96 indicate a low valuation relative to earnings and cash flow. Profitability metrics show a return on equity of 4.37% and return on assets of 3.54%, both below the industry_config median for medical equipment firms, which typically exceed 6% ROE and 4.5% ROA. Operating income of ¥1.11 billion and net income of ¥714 million reflect a 8.1% operating margin and 5.2% net margin, which are in line with the industry_config’s lower quartile. The company’s revenue is concentrated in Japan, with no disclosed international segments, and all revenue is attributed to a single business segment focused on medical devices. This geographic and product concentration increases exposure to domestic healthcare policy shifts and domestic demand fluctuations. Outlook data indicates a 3.2% year-over-year revenue growth for the current fiscal year, with a 4.1% increase projected for the following year. This growth trajectory is modest compared to the industry_config’s 5–7% average for medical equipment firms, suggesting limited expansion into new markets or product lines. Risk assessment highlights low liquidity and dilution risk, with no immediate filing-based flags detected. The company’s debt-to-equity ratio of 0.05 and long-term debt of ¥812 million indicate a conservative capital structure. No dilution potential is reported, and no adjustments were applied to valuation metrics. Recent filings and transcripts show no material changes in business strategy or financial position. The company’s latest actual revenue of ¥13.62 billion and EPS of ¥84.25 align with analyst estimates, indicating stable performance.